TetraLogic Pharmaceuticals Corporation
TLOG
Get informed when a big investor buys or sells
+ FollowMarket Cap$979
Close$
Share Statistics
| Market cap | $979.00 |
|---|---|
| Enterprise Value | $24.90 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-2.37 |
| Beta | 4.06 |
| Outstanding Shares | 24,769,083 |
Return
| Return on Equity | 147.90% |
|---|---|
| Return on Assets | -106.94% |
| Return on Invested Capital | -167.02% |
Valuation & Multiples
| P/E Ratio | 0 |
|---|---|
| PEG | 0 |
| Price to Sales | - |
| Price to Book Ratio | -0.0 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -0.51 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 1.24 |
| Debt to Equity | -1 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About TetraLogic Pharmaceuticals Corporation
29 employees
CEO: Dr. Yigong Shi Ph.D. TetraLogic Pharmaceuticals Corporation, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics in oncology and infectious diseases. It has two clinical-stage product candidates in de...